Gregorio Cortes-Maisonet
General Practice · San Juan, PRNPI 1639151616
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $20,266 of the $25,953 with a category attached, or 78.1%. Eli Lilly accounts for 82.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $12,421 and has fallen 88.0% since, to $1,495 in 2025. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $174.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$22K
- AbbVie$2K
- UCB GmbH$1K
- Lilly USA, LLC$367
- Novo Nordisk$296
- Merck$269
- plus $599 from 7 others
Across 1,449 payments — averaging $8934.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$7M
- Eli Lilly$1.3M
- E.r. Squibb & Sons, L.L.C.$1.3M
- AbbVie$1.1M
- Modernatx, Inc.$955K
- Takeda Pharmaceuticals U.S.A., Inc.$350K
- plus $958K from 11 others
What the payments were for
- Consulting fees$1,0504%
- Travel & lodging$20,26678%
- Food & beverage$4,63718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 99 | $21,513 |
| AbbVie | 10 | $1,669 |
| UCB GmbH | 8 | $1,241 |
| Lilly USA, LLC | 5 | $367 |
| Novo Nordisk | 12 | $296 |
| Merck | 2 | $269 |
| Novartis | 1 | $145 |
| Amgen | 1 | $125 |
| PBG Puerto Rico LLC | 1 | $92 |
| Eli Lilly Export S.A. Puerto Rico Branch | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 1 | $68 |
| AstraZeneca | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,953 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $18,710 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $17,371 |
| RybelsusSemaglutide | 13 | $14,587 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,724 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $9,261 |
| SynthroidLevothyroxine Sodium | 44 | $3,709 |
| Pentoxifylline | 30 | $1,501 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $1,322 |
| Atorvastatin Calcium | 83 | $1,004 |
| Levothyroxine Sodium | 50 | $791 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $776 |
| FenofibrateFenofibrate Nanocrystallized | 26 | $744 |
| Losartan Potassium | 71 | $741 |
| Glimepiride | 13 | $713 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 14 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $296 | $33,29732 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $38 | $12,04626 claims |
| AbbVieSynthroid | $1,669 | $3,70944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in San Juan
- William E TorresSan Juan$86K
- Vivian Tamayo AgraitSan Juan$64K
- Victor PalmerSan Juan$21K
- Jose Davila SanchezSan Juan$16K
- Hector Cintron ColonSan Juan$10K
- Gabriela TorresSan Juan$8K
- Orvil MartinezSan Juan$7K
- Carlos Henriquez FelipeSan Juan$6K
- Rene Echevarria CofinoSan Juan$6K
- Luis Marquez BabiloniaSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.